
AMENDMENT TRANSMITTAL LETTER					Docket No. NEL-0006
Application No.		Filing Date		Examiner	Art Unit
10/091,567-Conf. #7851		March 7, 2002		Myron G. Hi	
pplicant(s): Jon	<u> </u>		-ENCAPSUL	ATED PLASMID DN	IA ENCODING FOR
HEMAG	GGLUTININ PF	ROTEIN OF IN	IFLUENZA VI	RUS ——————	
Fransmitted here		THE COMMI			
The fee has beer					
		CLAIM	S AS AMENI	DED	
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	10	- 20 =	0	х	0.00
Independent Claims	4	- 3 =	1	86	86.00
Other fee (please specify): Petition for Extension of Time TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					110.00 196.00
x Large Entity	al fee is require	d for this ame	ndment	Small Entity	
X Please char	·	ount No	18-0013 iı	n the amount of \$ _	196.00
	ne amount of \$ credit card. Fo			the filing fee is enc	osed.
_	ssioner is heret d below. A dup	•	-	credit Deposit Accenclosed.	ount No18-0013
	ny overpaymer any additional fili		on processing	fees required under 3	37 CFR 1.16 and 1.17.
Robert S. Gree Attorney Reg. N				Dated:	October 3, 2003
RADER, FISHM 1233 20th Stree Washington, De	MAN & GRAUE et, N.W., Suite				

(202) 955-3750 DC115727





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Jonathan P. WONG et al.

Confirmation No.: 7851

Application No.: 10/091,567

Art Unit: 1648

Filed: March 7, 2002

Examiner: Myron G. Hill

For: NEL-006 DNA VACCINE USING

LIPOSOME-ENCAPSULATED PLASMID DNA ENCODING FOR HEMAGGLUTININ

PROTEIN OF INFLUENZA VIRUS

AMENDMENT

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the final Office Action dated June 3, 2003 (Paper No. 11), finally rejecting claims 8-13, 18 and 19, and prior to Continued Examination pursuant to a Request Fro Continued Examination submitted concurrently herewith, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.